REMODULIN IS A PROSTACYCLIN-CLASS THERAPY1

Treprostinil mechanism of action (MOA) targets 3 of the pathologic changes that occur in PAH1-3

Vasoconstriction
Treprostinil directly dilates pulmonary and systemic arterial vascular beds

Platelet aggregation
Treprostinil inhibits platelet aggregation

Smooth muscle proliferation
Treprostinil inhibits smooth muscle cell proliferation
PAH=pulmonary arterial hypertension.